Skip to main content
. Author manuscript; available in PMC: 2022 Nov 21.
Published in final edited form as: Nat Metab. 2022 Jun 20;4(6):724–738. doi: 10.1038/s42255-022-00583-z

Fig. 7 |. Loss of CA9 inhibits hypoxic cancer cell growth under aspartate limitation.

Fig. 7 |

a, Immunoblot analysis of CA9 in the indicated MIA PaCa-2 cell lines transduced with a control sgRNA or an sgRNA targeting CA9. GAPDH was used as a loading control. b,c, Quantification of ratio of percent Ki67 positive cells in hypoxic (pimonidazole positive) to neighbouring normoxic (pimonidazole negative) regions in MIA PaCa-2 parental tumours (b) MIA PaCa-2 GOT2 knockout tumours (c) transduced with a control sgRNA (sgControl) or sgCA9. Data are presented relative to values obtained for sgControl tumours. d, Representative immunofluorescent images of tumour xenografts derived from indicated MIA PaCa-2 cells stained for DAPI (nucleus), Ki67 (proliferation) and pimonidazole (hypoxia marker). Scale bar, 200 μM. c,d, Bars represent mean ± s.e.m. n = total numbers of fields evaluated from all five tumours analysed, 18, 20, 14 and 15 for each group, respectively. Statistical significance determined by a two-tailed Student’s t-test.